Agenda:

Welcome:        

Kurt Herrenknecht, PerkinElmer

"A new member in the Opera family "

 

Iris Schmitt, Evotec AG:

"A high content approach for the identification of genotype selective anti- tumor
drugs using synthetic lethal screening in human tumor cells "

 

Dorit Meyer; Max Planck Institute for Breeding Research Cologne:

"Understanding molecular mechanisms underlying the pathogen triggered PEN1
focal accumulation at fungal entry sites "

 

Coffee break:

 

Marnix Van Loock, Tibotec:

Title to be announced

 

Martin Stoeter, Max Planck Institute of Molecular Cell Biology and Genetics:  
“High Content RNAi Screening for Genome-Wide Functional Analysis to Identify 
Novel Regulators of Endocytotic Pathways”